Findings reveal immune markers influencing pregnancy outcomes in women with recurrent pregnancy loss, suggesting potential therapeutic targets.
Immune factors in the endometrium of women with recurrent pregnancy loss (RPL) appear to play a crucial role in the pathophysiology of a subset of RPL patients. Differences in the expression of five immune markers, CD138 (plasma cells), CD56 (uterine natural killer (uNK) cells), CD163 (M2 macrophages), soluble HLA-G and HLA-F, were studied in the preconceptional endometrium between women with RPL and control/reference women, and also between the proliferative and secretory phases. The RPL group included 96 patients. One reference group (n = 58) comprised women referred for IVF/ICSI treatment; another control group (n = 22) consisted of healthy fertile women. Endometrial biopsies were subjected to immunohistochemistry analysis; 118 biopsies from the proliferative phase, 55 from the secretory phase and three from inactive endometrium. Increased levels of CD56-positive uNK cells and sHLA-G expression in the proliferative phase and of CD138-positive plasma cells in the secretory phase were observed in the RPL group compared with the other groups. High expression of CD56 in uNK cells and high HLA-F-positive cell fraction in the glands in the proliferative phase served as negative predictors for achieving a successful pregnancy for women with RPL in Cox regression analyses. Follow-up for 45 months. A new finding was an intense sHLA-G staining of intracellular vesicles in the glands of some biopsies in the RPL group associated with the achievement of a healthy pregnancy. Increased levels of the preconceptional endometrial markers CD56 (uNK cells), HLA-F, sHLA-G and CD138 (plasma cells) may contribute to the pathophysiology of RPL.
No takes yet. Share an insight, caveat, or question.
Andersen et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: